Perspective Therapeutics enrols patients in melanoma drug trial
Source: Clinical Trials Arena, October 2023
Medical technology and radiopharmaceutical company Perspective Therapeutics has enrolled the first patient cohort in its Phase I/IIa dose escalation study of ²¹²Pb-VMT01 to treat MC1R-positive metastatic melanoma.
The dose escalation and dose expansion study enrolled subjects with histologically confirmed melanoma and positive MC1R imaging scans.
Its first portion is a dose escalation phase that aims to determine the maximum tolerated radioactivity dose (MTD) or maximum feasible radioactivity dose (MFD) after a single administration of ²¹²Pb-VMT01.